Health
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the ongoing open-label extension (OLE) of the Pha
About this update from Tg Therapeutics, Inc.
[{"type":"image","alt":"TG Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TG Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kJRuP1U4UFEdpu7yaRZIrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1","width":300,"height":79}},"lazy":false},{"type":"text","content":"During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment","length":150,"tagName":"p"},{"type":"text","content":"Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment","length":152,"tagName":"p"},{"type":"text","content":"NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the ongoing open-label extension (OLE) of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS). The manuscript, authored by Bruce A. C. Cree, MD, PhD, MAS, of the University of California, San Francisco, and colleagues, was published in JAMA Neurology. The publication presents a comprehensive long-term evaluation of BRIUMVI and demonstrates durable clinical efficacy, low relapse rates, and a consistent safety profile with up to five years of continuous treatment. Additional details from the publication are included below.","length":761,"tagName":"p"},{"type":"text","content":"Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “Acceptance of these five-year ULTIMATE I & II results in JAMA Neurology represents a major milestone for TG Therapeutics and the MS field. These data underscore not only the durable clinical efficacy and consistent safety of BRIUMVI through extended treatment, but also our commitment to advancing long-term evidence that helps clinicians and patients make informed treatment decisions. We believe these findings support BRIUMVI’s continued role as a valuable option for people living with relapsing MS.”","length":...